行情

RVNC

RVNC

Revance
NASDAQ

实时行情|Nasdaq Last Sale

25.33
+0.62
+2.51%
盘后: 25.41 +0.08 +0.32% 16:11 02/14 EST
开盘
24.74
昨收
24.71
最高
25.93
最低
24.35
成交量
77.89万
成交额
--
52周最高
27.06
52周最低
9.88
市值
13.07亿
市盈率(TTM)
-6.6890
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

RVNC 新闻

  • Revance to Release Fourth Quarter and Full Year 2019 Financial Results on Monday, February 24, 2020
  • Business Wire.3天前
  • Revance down 9% premarket after pricing upsized convertible debt offering
  • Seeking Alpha - Article.5天前
  • The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology
  • Benzinga.6天前
  • Revance Announces Proposed Private Offering of $200 Million of Convertible Senior Notes Due 2027
  • Business Wire.02/10 21:08

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
-0.16%

热门股票

名称
价格
涨跌幅

RVNC 简况

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable. RT002 injectable utilizes botulinum toxin-peptide complex in a saline-based formulation. In RT002 injectable, the peptide interacts with both extracellular structures and cell surface receptors in the targeted muscle. This interaction restricts the toxin molecule to the target site and reduces unwanted spread to other neighboring muscles. It is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis.
展开

Webull提供Revance Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。